OncoMatch

OncoMatch/Clinical Trials/NCT05445778

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Is NCT05445778 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Mirvetuximab soravtansine plus Bevacizumab and Bevacizumab for ovarian cancer.

Phase 3RecruitingAbbVieNCT05445778Data as of May 2026

Treatment: Mirvetuximab soravtansine plus Bevacizumab · Bevacizumab — GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Biomarker criteria

Required: FOLR1 high expression (high)

Prior therapy

Max 1 prior line
Min 1 prior line

Must have received: platinum-based chemotherapy — frontline (first-line)

Relapsed disease after frontline (first-line) platinum-based chemotherapy and must be platinum-sensitive

Cannot have received: MIRV or other FRα-targeting agents

Received prior MIRV or other FRα-targeting agents

Cannot have received: radiotherapy

Exception: whole-pelvis or wide-field

Prior or whole-pelvis or wide-field radiotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Usa Mitchell Cancer Institute /ID# 269661 · Mobile, Alabama
  • Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 · Phoenix, Arizona
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 · Irvine, California
  • Moores Cancer Center at UC San Diego /ID# 269564 · La Jolla, California
  • Kaiser Permanente - Los Angeles Medical Center /ID# 269541 · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify